Publication

Article

Physician's Money Digest
April15 2005
Volume 12
Issue 7

Model Portfolio Series: Aggressive Growth

Following is the aggressive growth model portfolio's quarterly updated information. During the next 2 months, we'll update the equity income and conservative growth portfolios. During the past quarter, ArvinMeritor Inc and Supervalu Inc were replaced with Compania de Telecomunicaciones de Chile SA and Genentech Inc in the portfolio. As of Mar. 15, 2005, the portfolio consisted of 15 stocks selected based on the following analyst ratings: B=buy; N=neutral; R=reduce; NR=not rated; and the following predictability levels: 1=higher; 2=lower. These ratings translate into the following stock movements: B1/B2=buy; N1/N2=hold; R1/R2=sell. Since the data may have changed, contact 800-316-7015 or paul.namm@ubs.com for updates.

Since this portfolio is hypothetical, it does not contain any investor assets. The decisions were not made under the same conditions as those for an actual account. There can be no assurance that the author would have made the same decisions or achieved the same level of performance if managing an actual account. The hypothetical performance of this model may be of limited value in evaluating the author's past or future performance. The author manages other hypothetical accounts, as well as actual taxable and tax-exempt accounts, and recommends the purchase or sale of securities for individuals and institutions. The performance of his actual accounts may be materially better or worse than that of the model portfolio.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.